从传统小分子到小分子靶向药物,再逐步拓展至大分子、细胞疗法与mRNA疗法,生物医药领域的每一次研发突破都在为临床诊疗拓宽路径。其中,mRNA技术在新冠疫情期间通过疫苗研发迅速完成商业化验证,Moderna、BioNTech和CureVac借此成长为全球mRNA巨头。然而,随着疫情影响消退,mRNA行业也步入转型关键期。 在技术应用层面,麦高证券研报指出,mRNA肿瘤疫苗有望成为一种适用于泛癌种、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.